Novo Holdings leads US$50M investment in South Asia–based MedGenome

BANGALORE, INDIA – FOSTER CITY, USA – SINGAPORE – 30 August 2022 – Novo Holdings A/S (“Novo Holdings” and “NH”), a leading international investor in healthcare and life sciences, today announces it has led a $50 million investment into MedGenome, a leading genetic diagnostics, research and data company, alongside its existing investors, LeapFrog Investments and Sofina. The investment will give Novo Holdings a significant minority stake in MedGenome, and Dr Amit Kakar, Senior Partner, and Navjeewan Khosla, Principal, will join the Board of MedGenome, as Director and Observer, respectively.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...